Shuttle Pharmaceuticals (SHPH) announced a sponsored research agreement with the University of California, San Francisco, UCSF, to advance pre-clinical development of Shuttle Diagnostics’ ligand to the prostate-specific membrane antigen, PSMA, as a potential diagnostic and therapeutic, or theranostic, molecule. Theranostic molecules are suitable for diagnosis and therapy of cancers.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SHPH: